drugset / Trial / NCT04997941

Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients

NCT04997941

Phase 2 Active not recruiting 238 enrolled Seoul National University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

MORE-T trial is designed to investigate the effect of Tamoxifen 40mg (vs. Tamoxifen 20mg) for 2wks in presurgical setting. The greater reduction in Ki-67 might be observed in Tamoxifen 40mg arm compared to the Tamoxifen 20mg arm. Open Label, Phase 2, Randomized with 1:1 allocation

Timeline

Start
2021-10-21
Primary completion
2024-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamoxifen Small molecule 20 mg Oral
Subject Tamoxifen Small molecule 40 mg Oral